4.6 Article

Abnormal activation of the Akt-GSK3 beta signaling pathway in peripheral blood T cells from patients with systemic lupus erythematosus

Journal

CELL CYCLE
Volume 8, Issue 17, Pages 2789-2793

Publisher

TAYLOR & FRANCIS INC
DOI: 10.4161/cc.8.17.9446

Keywords

systemic lupus erythematosus (SLE); T lymphocytes; cell cycle; Akt; GSK3 beta

Categories

Funding

  1. National Natural Science Foundation of China [30800336]
  2. Science and Technology Foundation of Guangdong Province [2006B36005006]
  3. Medical Science & Technique Research Foundation of Guangdong Province [A647]

Ask authors/readers for more resources

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease accompanied by the activation and proliferation of T cells and B cells. In this study, we found that the distributions of lymphocytes obtained from patients with SLE or SLE with renal disease (RSLE) were reduced in the G(0)/G(1) phase and were elevated in the S phase after phytohemagglutinin treatment. Increased expression of CDK2 and decreased expression of cyclin-dependent kinase inhibitors p27(Kip1) and p21(WAF1/CIP1) were observed in RSLE and SLE lymphocytes. The phosphorylation levels of Akt473 and GSK3 beta (ser9) were increased in lymphocytes from the patients. Moreover, inhibition of GSK3 beta with lithium chloride or SB216763 induced T cell proliferation, and the most significant effects were observed in RSLE lymphocytes. These results indicate that upregulation of CDKs and downregulation of p27(Kip1) and p21(WAF1/CIP1) increased the proliferation of T lymphocytes in SLE patients. Abnormal activation of the Akt-GSK3 beta signaling pathway increased the proliferation of lupus lymphocytes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available